The candidate is in phase II studies for hidradenitis suppurativa (HS) and atopic dermatitis (AD). Shares of KYMR have surged 25.5% year to date against the industry's decline of 7.1%. KT-474 (SAR444656) is a first-in-class IRAK4 degrader in development for the treatment of immuneinflammatory diseases with significant patient need, such as hidradenitis suppurativa (HS) and atopic dermatitis (AD). Sanofi informed Kymera about the decision to expand the study after a review of preliminary safety and efficacy ...